Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100489Source: DataRank Database

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene is a research paper published in JTO Clinical and Research Reports (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: goldTopics (25)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Emmeline C. Academia ORCID,Soravis A. Osataphan,Deepa Rangachari ORCID,Sheida Sharifi,Paul A. VanderLaan ORCID

Live enrichment

PubMed:36994308 OpenAlex:https://openalex.org/W4321769350

National Cancer Institute

Grant: R37 CA218707

National Institutes of Health

Grant: 5R37CA218707-07

Unmet needs for specific subsets of EGFR mutated lung cancer

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by-nc-nd

journalhttp://www.jtocrr.org/article/S2666364323000280/pdf

publisherhttp://www.jtocrr.org/article/S2666364323000280/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666364323000280?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364323000280?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtocrr.2023.100489

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Genomics and Diagnostics03 medical and health sciences0302 clinical medicine

Keywords

ExonLung cancerAlectinibCancer researchAnaplastic lymphoma kinaseAdenocarcinomaBiologyROS1ALK inhibitorMolecular biologyGeneCancerGeneticsMedicinePathologyDeletionALKCase reportNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being